BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Information letter on Ammonaps® (sodium phenylbutyrate) tablets and granules: Treatment only if no alternative is available

Active substance: sodium phenylbutyrate

In view of failings found in the manufacturing site of Ammonaps® (sodium phenylbutyrate) the company Swedish Orphan Biovitrum International AB (Sobi) is circulating information on temporary precautionary measures regarding treatment with Ammonaps® tablets and granules.

Download DHPC/Information letter , Download_VeroeffentlichtAm_EN PDF, 422KB, File is accessible